<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ophthalmology</journal-id><journal-title-group><journal-title xml:lang="ru">Офтальмология</journal-title><trans-title-group xml:lang="en"><trans-title>Ophthalmology in Russia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1816-5095</issn><issn pub-type="epub">2500-0845</issn><publisher><publisher-name>Ophthalmology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18008/1816-5095-2022-3-594-602</article-id><article-id custom-type="elpub" pub-id-type="custom">ophthalmology-1927</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ И ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL &amp; EXPERIMENTAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Жидкостная биопсия при увеальной меланоме. Есть ли смысл?</article-title><trans-title-group xml:lang="en"><trans-title>Liquid Biopsy for Uveal Melanoma. Does It Make Sense?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0623-4217</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ованесян</surname><given-names>В. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Ovanesyan</surname><given-names>V. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>соискатель,</p><p>Волоколамское шоссе, 91, Москва, 125310</p></bio><bio xml:lang="en"><p>applicant,</p><p>Volokolamskoe highway, 91, Moscow, 125371</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3175-9592</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лихванцева</surname><given-names>В. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Likhvantseva</surname><given-names>V. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, Волоколамское шоссе, 91, Москва, 125310;</p><p>профессор, консультант, ул. Гамалеи, 15, Москва, 123098</p></bio><bio xml:lang="en"><p>МD, Professor, Volokolamskoe highway, 91, Moscow, 125371;</p><p>consultant, Gamalei str., 15, Moscow, 123098</p></bio><email xlink:type="simple">likhvantseva-4@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рычкова</surname><given-names>С. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Rychkova</surname><given-names>S. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доцент кафедры офтальмологии,</p><p>ул. Гамалеи, 15, Москва, 123098</p></bio><bio xml:lang="en"><p>Associate Professor,</p><p>Gamalei str., 15, Moscow, 123098</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сельков</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Selkov</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>заведующий отделом иммунологии и межклеточных взаимодействий,</p><p>Менделеевская линия, 3, Санкт-Петербург, 199034</p></bio><bio xml:lang="en"><p>head of the Department of immunology and intercellular interactions,</p><p>Mendeleevskaya Line, 3, St. Petersburg, 199034</p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФПК «Академия постдипломного образования» ФГБУ «Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий» Федерального медико-биологического агентства</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Academy of Postgraduate Education of the Federal Scientific and Clinical Center for Specialized Medical Assistance and&#13;
Medical Technologies of FMBA of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФПК «Академия постдипломного образования» ФГБУ «Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий» Федерального медико-биологического агентства;&#13;
ФГБУ ГНЦ «Федеральный медицинский биофизический центр им. А.И. Бурназяна» Федерального медико-биологического агентства</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Academy of Postgraduate Education of the Federal Scientific and Clinical Center for Specialized Medical Assistance and&#13;
Medical Technologies of FMBA of Russia;&#13;
A.I. Burnazyan Federal Biophysical Center of FMBA of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Медико-биологический университет инноваций и непрерывного образования ФГБУ ГНЦ РФ «Федеральный биофизический центр им. А.И. Бурназяна» Федерального медико-биологического агентства</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Burnazyan Medical-Biological University of Innovation and Continuing Education, Federal Medical-Biological Agency</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт акушерства, гинекологии и репродуктологии им. Д.О. Отта»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Obstetrics, Gynecology and Reproduction named after D.O. Ott</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>07</day><month>10</month><year>2022</year></pub-date><volume>19</volume><issue>3</issue><fpage>594</fpage><lpage>602</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ованесян В.Э., Лихванцева В.Г., Рычкова С.И., Сельков С.А., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Ованесян В.Э., Лихванцева В.Г., Рычкова С.И., Сельков С.А.</copyright-holder><copyright-holder xml:lang="en">Ovanesyan V.E., Likhvantseva V.G., Rychkova S.I., Selkov S.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.ophthalmojournal.com/opht/article/view/1927">https://www.ophthalmojournal.com/opht/article/view/1927</self-uri><abstract><sec><title>Цель работы</title><p>Цель работы: изучить информативность и целесообразность жидкостной биопсии при увеальной меланоме (УМ).</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Выполняли жидкостную биопсию (синоним: биопсия стекловидной жидкости, СТЖ) энуклеированных глаз с УМ. Пробы СТЖ использовали для количественной оценки концентрации про-(IL-8, angiogenin, TNF-α, VEGF, bFGF) и антиангиогенных (IFN-α, TGF-β, IFN-γ) факторов роста методом мультиплексной проточной цитометрии, сравнивали с показателями пациентов с сенильной катарактой.</p></sec><sec><title>Результаты</title><p>Результаты. Жидкостная биопсия предоставила ценную и достоверную информацию о спектре цитокинов и их количественных показателях в СТЖ глаз с УМ. По сравнению с сенильной катарактой в СТЖ глаз с УМ имело место достоверное повышение частоты обнаружения уровня проангиогенных цитокинов TNF-α (80,0 % против 47,5 %, р &lt; 0,05; Мср ± m: 4,3 ± 1,1 пг/мл против 1,4 ± 0,3 пг/мл, р &lt; 0,05), ИЛ-8 (100 % против 75 %, р &lt; 0,01; 323,2 ± 227,9 пг/мл против 8,5 ± 1,5 пг/мл, р &lt; 0,001), ангиогенина (11704,9 ± 1767,7 пг/мл против 2820,15 ± 1404,90 пг/мл, р &lt; 0,01), VEGF (100,0 % против 68,2 %; р &lt; 0,05; 471,49 ± 154,60 пг/мл против 18,4 ± 3,2 пг/мл, р &lt; 0,05) и bFGF (60,0 % против 26,7 %, р &lt; 0,05; Мср: 44,6 ± 16,2 против 2,7 ± 1,0, р &lt; 0,001). В обеих группах больных не выявляли антиангиогенный фактор TGF-β, но концентрация ИФН-γ была обнаружена в пяти из девяти проб на уровне 14,9 ± 12,2 пг/мл, а уровни ИФН-α при УМ были в 4 раза выше: 17,6 ± 3,9 пг/мл против 4,4 ± 0,4 пг/мл (р &lt; 0,05).</p></sec><sec><title>Заключение</title><p>Заключение. Жидкостная биопсия глаз с УМ при использовании мультиплексной проточной цитометрии может стать ценным и высокоинформативным инструментом для изучения фенотипов УМ, при разработке и выборе молекулярных мишеней антиангиогенной, иммунной или иной таргетной терапии. Повышенные уровни проангиогенных факторов роста (IL-8, aнгиогенина, TNF-α, VEGF и bFGF), выявленные в СТЖ глаз с УМ, свидетельствуют о присутствии одновременно трех механизмов стимуляции ангиогенеза, два из которых не зависят от VEGF, действуют самостоятельно и независимо и могут проявлять синергизм. Недостаточно высокие уровни интерферонов (ИФН-γ и ИФН-α) на фоне отсутствия TGF-β в стекловидной жидкости позволяют думать о том, что подавлен контроль регуляции природного ангиостатического звена ангиогенеза на глазах с УМ. Высокие уровни цитокинов с плюрипотентными (проангиогенными и провоспалительными) свойствами свидетельствуют о том, что при опухолях хориоидеи воспаление может играть роль промотора ангиогенеза. </p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose</title><p>Purpose: to study the informativeness and appropriateness of liquid biopsy in uveal melanoma (UM).</p></sec><sec><title>Material and methods</title><p>Material and methods. Performed a liquid biopsy (synonym: vitreous fluid biopsy, CST) of enucleated eyes with UM. CST samples were used to quantify the concentration of pro-(IL-8, angiogenin, TNF-α, VEGF, bFGF) and antiangiogenic (IFN-α, TGF-β, IFN-γ) growth factors by multiplex flow cytometry. Compared with the indicators of patients with senile cataracts.</p></sec><sec><title>Results</title><p>Results. Liquid biopsy provided valuable and reliable information about the spectrum of cytokines and their quantitative indicators in the CTZ of the eyes with UM. Compared with senile cataracts in the vitreous fluid of the eyes with UM, there was a significant increase in the frequency of detection and level of proangiogenic cytokines TNF-α (80.0 % vs. 47.5 %, p &lt; 0.05; Msr ± m: 4.3 ± 1.1 pg/ml against 1.4 ± 0.3 pg/ml, p &lt; 0.05), IL-8 (100 % vs. 75 %, p &lt; 0.01; 323.2 ± 227.9 pg/ml versus 8.5 ± 1.5 pg/ml, r &lt; 0.001), angiogenin (11704.9 ± 1767.7 pg/ml versus 2820.15 ± 1404.90 pg/ml, r &lt; 0.01), VEGF (100.0 % vs. 68.2 %; p &lt; 0.05; 471.49 ± 154.60 pg/ml vs. 18.4 ± 3.2 pg/ml, p &lt; 0.05; 471.49 ± 154.60 pg/ml vs. 18.4 ± 3.2 pg/ml, p &lt; 0.05) and bFGF (60.0 % vs. 26.7 %, p &lt; 0.05; Msr: 44.6 ± 16.2 vs. 2.7 ± 1.0, p &lt; 0.001). In both groups of patients, the antiangiogenic factor TGF-β was not detected, but the concentration of IFN-γ was found in five of the eight samples at the level of 14.9 ± 12.2 pg/ml, and the levels of IFN were 4 times higher: 17.6 ± 3.9 pg/ml against 4.4 ± 0.4 pg/ml (p &lt; 0.05).</p></sec><sec><title>Conclusions</title><p>Conclusions. Liquid eye biopsy with UM using multiplex flow cytometry can be a valuable and highly informative tool for studying UM phenotypes, in the development and selection of molecular targets for antiangiogenic or other targeted therapies. Elevated levels of proangiogenic growth factors (IL-8, angiogenin, TNF-α, VEGF and bFGF) in vitreous fluid in UM indicate the presence simultaneously of three mechanisms for stimulating angiogenesis, two of which are independent of VEGF, act independently, and may show synergism. Insufficiently high levels of interferons (IFN-γ and IFN-α) against the background of the absence of TGF-β in the vitreous fluid allow us to think that the secretion and control of the regulation of the natural angiostatic link of angiogenesis in the eyes with choroidal melanoma is suppressed. High levels of cytokines with pluripotent (proangiogenic and pro-inflammatory) properties indicate that in choroidal tumors, inflammation may play the role of a promoter of angiogenesis. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>жидкостная биопсия</kwd><kwd>увеальная меланома</kwd><kwd>факторы роста</kwd><kwd>стекловидная жидкость</kwd><kwd>ангиогенез</kwd></kwd-group><kwd-group xml:lang="en"><kwd>liquid eye biopsy</kwd><kwd>uveal melanoma</kwd><kwd>growth factors</kwd><kwd>vitreous fluid</kwd><kwd>angiogenesis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Yang J., Manson D.K., Marr B.P., Carvajal R.D. Treatment of uveal melanoma: Where are we now? Ther. Adv. Med. Oncol. 2018;10:1–17. DOI: 10.1177/1758834018757175</mixed-citation><mixed-citation xml:lang="en">Yang J., Manson D.K., Marr B.P., Carvajal R.D. Treatment of uveal melanoma: Where are we now? Ther. Adv. Med. Oncol. 2018;10:1–17. DOI: 10.1177/1758834018757175</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Aronow M.E., Topham K., Singh A.D. Uveal Melanoma: 5Year Update on Incidence, Treatment, and Survival (SEER 1973–2013). Ocul. Oncol. Pathol. 2018;4:145– 151. DOI: 10.1159/000480640</mixed-citation><mixed-citation xml:lang="en">Aronow M.E., Topham K., Singh A.D. Uveal Melanoma: 5Year Update on Incidence, Treatment, and Survival (SEER 1973–2013). Ocul. Oncol. Pathol. 2018;4:145– 151. DOI: 10.1159/000480640</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Singh A.D., Turell M.E., Topham A.K. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011;118(9):1881–1885. DOI: 10.1016/j.oph tha.2011.01.040</mixed-citation><mixed-citation xml:lang="en">Singh A.D., Turell M.E., Topham A.K. Uveal melanoma: trends in incidence, treat ment, and survival. Ophthalmology 2011;118(9):1881–1885. DOI: 10.1016/j.oph tha.2011.01.040</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Саакян С.В., Мякошина Е.Б. Захарова Г.П, Гарри Д., Выживаемость пациентов с меланомой малых и средних размеров. Эффективная фармакотерапия. 2020:16;(21):18–22. DOI: 10.33978/23073586202016211822</mixed-citation><mixed-citation xml:lang="en">Saakyan S.V., Myakoshina E.B. Zaharova G.P, Garri D. Surviv al of patients with small to mediumsized melanoma. Effective pharmacotherapy = Effektivnaya farmakoterapiya. 2020:16;(21):18–22 (In Russ). DOI: 10.33978/23073586202016211822</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Amaro A., Gangemi R., Piaggio F., Angelini G., Barisione G., Ferrini S., Pfeffer U. The biology of uveal melanoma. Cancer Metastasis Rev. 2017:36:109–140. DOI: 10.1007/s1055501796633</mixed-citation><mixed-citation xml:lang="en">Amaro A., Gangemi R., Piaggio F., Angelini G., Barisione G., Ferrini S., Pfeffer U. The biology of uveal melanoma. Cancer Metastasis Rev. 2017:36:109–140. DOI: 10.1007/s1055501796633</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Castet F., GarciaMulero S., SanzPamplona R., Cuellar A., Casanovas O., Caminal J.M., Piulats J.M. Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope? Cancers. 2019;11:834. DOI: 10.3390/cancers11060834</mixed-citation><mixed-citation xml:lang="en">Castet F., GarciaMulero S., SanzPamplona R., Cuellar A., Casanovas O., Caminal J.M., Piulats J.M. Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope? Cancers. 2019;11:834. DOI: 10.3390/cancers11060834</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">AsencioDuran M., DabadMoreno J.V., VicandiPlaza B., ManzanoMuñoz B., CapoteDíez M., AmorenaSantisteban G. The Vitreous Body and Its Role in the Diagnosis of Eye Pathologies Medical Research Archives. 2021;9(9):2–24. DOI: 10.18103/mra.v9i9.2543</mixed-citation><mixed-citation xml:lang="en">AsencioDuran M., DabadMoreno J.V., VicandiPlaza B., ManzanoMuñoz B., CapoteDíez M., AmorenaSantisteban G. The Vitreous Body and Its Role in the Diagnosis of Eye Pathologies Medical Research Archives. 2021;9(9):2–24. DOI: 10.18103/mra.v9i9.2543</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lee C.S., Jun I.H., Kim T.I., Byeon S.H., Koh H.J., Lee S.C. Expression of 12 cy tokines in aqueous humour of uveal melanoma before and after combined Ru thenium106 brachytherapy and transpupillary thermotherapy. Acta Ophthalmol. 2012;90:e314–e320. DOI: 10.1167/iovs.1210123</mixed-citation><mixed-citation xml:lang="en">Lee C.S., Jun I.H., Kim T.I., Byeon S.H., Koh H.J., Lee S.C. Expression of 12 cy tokines in aqueous humour of uveal melanoma before and after combined Ru thenium106 brachytherapy and transpupillary thermotherapy. Acta Ophthalmol. 2012;90:e314–e320. DOI: 10.1167/iovs.1210123</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ly L.V., Bronkhorst I.H., van Beelen E. Inflammatory cytokines in eyes with uveal melanoma and relation with macrophage infiltration. Invest Ophthalmol Vis Sci. 2010;51:5445–5451. DOI: 10.1167/iovs.105526</mixed-citation><mixed-citation xml:lang="en">Ly L.V., Bronkhorst I.H., van Beelen E. Inflammatory cytokines in eyes with uveal melanoma and relation with macrophage infiltration. Invest Ophthalmol Vis Sci. 2010;51:5445–5451. DOI: 10.1167/iovs.105526</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">NagarkattiGude N., Bronkhorst I.H.G., van Duinen S.G., Luyten G.P.M., rtine J. Jager M.J. Сytokines and Chemokines in the Vitreous Fluid of Eyes with Uveal Melanoma. Investigative Ophthalmology &amp; Visual Science. 2012;53:6748–6755. DOI: 10.1167/iovs.1210123</mixed-citation><mixed-citation xml:lang="en">NagarkattiGude N., Bronkhorst I.H.G., van Duinen S.G., Luyten G.P.M., rtine J. Jager M.J. Сytokines and Chemokines in the Vitreous Fluid of Eyes with Uveal Melanoma. Investigative Ophthalmology &amp; Visual Science. 2012;53:6748–6755. DOI: 10.1167/iovs.1210123</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kivela T., Simpson E.R., Grossniklaus H.E., Jager M.J., Sough A.D., Caminal J.M. Uveal melanoma. In: AJCC Cancer Staging Manual, 8th. New York, Springer: 2017. P. 805–817.</mixed-citation><mixed-citation xml:lang="en">Kivela T., Simpson E.R., Grossniklaus H.E., Jager M.J., Sough A.D., Caminal J.M. Uveal melanoma. In: AJCC Cancer Staging Manual, 8th. New York, Springer: 2017. P. 805–817.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Shain H., Bagger M.M., Yu R., Chang D., Liu Sh., Vemula S., Weier J.F., Wadt K., Heegaard S., Bastian B.S., Kiilgaard J.F The genetic evolution of metastatic uveal melanoma. Nature Genetics. 2019;51:1123–1130. DOI: 10.1038/s4158801904409</mixed-citation><mixed-citation xml:lang="en">Shain H., Bagger M.M., Yu R., Chang D., Liu Sh., Vemula S., Weier J.F., Wadt K., Heegaard S., Bastian B.S., Kiilgaard J.F The genetic evolution of metastatic uveal melanoma. Nature Genetics. 2019;51:1123–1130. DOI: 10.1038/s4158801904409</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kaliki S., Shields C.L., Shields J.A. Uveal melanoma: Estimating prognosis Indian Journal of Ophthalmology. 2017;63(2):93–101. DOI: 10.4103/03014738.154367</mixed-citation><mixed-citation xml:lang="en">Kaliki S., Shields C.L., Shields J.A. Uveal melanoma: Estimating prognosis Indian Journal of Ophthalmology. 2017;63(2):93–101. DOI: 10.4103/03014738.154367</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Самкович Е.В., Панова И.Е. Возможности идентификации сосудистой сети меланомы хориоидеи. Офтальмология. 2020;17(2):172–180. DOI: 10.18008/1816509520202172180</mixed-citation><mixed-citation xml:lang="en">Samkovich E.V., Panova I.E. Possibilities of identification of the vascular network of choroidal mela noma. Оphthalmology in Russia = Oftal’mologiya. 2020;17(2):172–180 (In Russ.). DOI: 10.18008/1816509520202172180</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Гришина Е.Е. Анализ выживаемости больных увеальной меланомой при органосохранном и ликвидационном лечении. Альманах клинической медицины 2018;46(1):68–75. DOI: 10.18786/2072050520184616875</mixed-citation><mixed-citation xml:lang="en">Grishina E.E. Analysis of survival of patients with uveal melanoma in organpreserving and liquidation treatment. Almanac of Clinical Medicine  = Al’manah klinicheskoy mediciny. 2018;46(1):6875 (In Russ.)]. DOI: 10.18786/2072050520184616875</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Virgili G., Gatta G., Ciccolallo L., Capocaccia R., Biggeri A., Crocetti E. Sur vival in patients with uveal melanoma in Europe. Archives of Ophthalmology. 2008;126(10):1413–1418. DOI: 10.1001/archopht.126.10.1413</mixed-citation><mixed-citation xml:lang="en">Virgili G., Gatta G., Ciccolallo L., Capocaccia R., Biggeri A., Crocetti E. Sur vival in patients with uveal melanoma in Europe. Archives of Ophthalmology. 2008;126(10):1413–1418. DOI: 10.1001/archopht.126.10.1413</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Chew A.L., Spilsbury K., Isaacs T.W. Survival from uveal melanoma in Western Australia 1981–2005. Clinical &amp; Experimental Ophthalmology. 2015;43(5):422– 428. DOI: 10.1111/ceo.12490</mixed-citation><mixed-citation xml:lang="en">Chew A.L., Spilsbury K., Isaacs T.W. Survival from uveal melanoma in Western Australia 1981–2005. Clinical &amp; Experimental Ophthalmology. 2015;43(5):422– 428. DOI: 10.1111/ceo.12490</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">De Angelis R., Sant M., Coleman M.P., Francisci S., Bail, P., Pierannunzio D., Trama A. Cancer survival in Europe 1999–2007 by country and age: results of EURO CARE5 — a populationbased study. The Lancet Oncology. 2014;15(1):23–34. DOI: 10.1016/S14702045(13)705461</mixed-citation><mixed-citation xml:lang="en">De Angelis R., Sant M., Coleman M.P., Francisci S., Bail, P., Pierannunzio D., Trama A. Cancer survival in Europe 1999–2007 by country and age: results of EURO CARE5 — a populationbased study. The Lancet Oncology. 2014;15(1):23–34. DOI: 10.1016/S14702045(13)705461</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA: Cancer Journal for Clinicians. 2016;66(1):7–30. DOI: 10. 3322/caac.21332</mixed-citation><mixed-citation xml:lang="en">Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA: Cancer Journal for Clinicians. 2016;66(1):7–30. DOI: 10. 3322/caac.21332</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kuk D., Shoushtari A., Barker C., Panageas K., Munhoz R., Momtaz P., Ariyan C., Brady M., Coit D., Bogatch K. Prognosis of Mucosal, Uveal, Acral, Nonacral Cuta neous, and Unknown Primary Melanoma from the Time of First Metastasis. Oncologist. 2016;21:848–854. DOI: 10.1634/theoncologist.20150522</mixed-citation><mixed-citation xml:lang="en">Kuk D., Shoushtari A., Barker C., Panageas K., Munhoz R., Momtaz P., Ariyan C., Brady M., Coit D., Bogatch K. Prognosis of Mucosal, Uveal, Acral, Nonacral Cuta neous, and Unknown Primary Melanoma from the Time of First Metastasis. Oncologist. 2016;21:848–854. DOI: 10.1634/theoncologist.20150522</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Pons F., Plana M., Caminal J.M., Pera J., Fernandes I., Perez J., GarciaDelMuro X., Marcoval J., Penin R., Fabra A. Metastatic uveal melanoma: Is there a role for con ventional chemotherapy? — A single center study based on 58 patients. Melanoma Res. 2011;21:217–222. DOI: 10.1097/CMR.0b013e3283457726</mixed-citation><mixed-citation xml:lang="en">Pons F., Plana M., Caminal J.M., Pera J., Fernandes I., Perez J., GarciaDelMuro X., Marcoval J., Penin R., Fabra A. Metastatic uveal melanoma: Is there a role for con ventional chemotherapy? — A single center study based on 58 patients. Melanoma Res. 2011;21:217–222. DOI: 10.1097/CMR.0b013e3283457726</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Carvajal R.D., Schwartz G.K., Tezel T., Marr B., Francis J.H., Nathan P.D. Metastatic disease from uveal melanoma: Treatment options and future prospects. Br. J. Ophthalmol. 2017;101:38–44. DOI: 10.1136/bjophthalmol2016309034</mixed-citation><mixed-citation xml:lang="en">Carvajal R.D., Schwartz G.K., Tezel T., Marr B., Francis J.H., Nathan P.D. Metastatic disease from uveal melanoma: Treatment options and future prospects. Br. J. Ophthalmol. 2017;101:38–44. DOI: 10.1136/bjophthalmol2016309034</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Niederkorn J.Y. Immune escape mechanisms of intraocular tumors. Prog Retin Eye Res. 2009;28:329–347. DOI: 10.1016/j.preteyeres.2009.06.002</mixed-citation><mixed-citation xml:lang="en">Niederkorn J.Y. Immune escape mechanisms of intraocular tumors. Prog Retin Eye Res. 2009;28:329–347. DOI: 10.1016/j.preteyeres.2009.06.002</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Yang W., Chen P.W., Li H. PDL1: PD1 interaction contributes to the functional suppression of Tcell responses to human uveal melanoma cells in vitro. Invest Ophthalmol Vis Sci. 2008;49:2518–2525. DOI: 10.1167/iovs.071606</mixed-citation><mixed-citation xml:lang="en">Yang W., Chen P.W., Li H. PDL1: PD1 interaction contributes to the functional suppression of Tcell responses to human uveal melanoma cells in vitro. Invest Ophthalmol Vis Sci. 2008;49:2518–2525. DOI: 10.1167/iovs.071606</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">SteinStreilein J., Streilein J.W. Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy. Int Rev Immunol. 2002;21:123–152. DOI: 10.1080/08830180212066</mixed-citation><mixed-citation xml:lang="en">SteinStreilein J., Streilein J.W. Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy. Int Rev Immunol. 2002;21:123–152. DOI: 10.1080/08830180212066</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Brahmer J., Reckamp K.L., Baas P. Nivolumab versus Docetaxel in Advanced SquamousCell NonSmallCell Lung Cancer. N Engl J Med. 2015;373:123–135. DOI: 10.1056/NEJMoa1504627</mixed-citation><mixed-citation xml:lang="en">Brahmer J., Reckamp K.L., Baas P. Nivolumab versus Docetaxel in Advanced SquamousCell NonSmallCell Lung Cancer. N Engl J Med. 2015;373:123–135. DOI: 10.1056/NEJMoa1504627</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Dunn G.P., Bruce A.T., Ikeda H. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–998. DOI: 10.1038/ni1102991</mixed-citation><mixed-citation xml:lang="en">Dunn G.P., Bruce A.T., Ikeda H. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–998. DOI: 10.1038/ni1102991 28. Teng M.W., Ngiow S.F., Ribas A. Classifying Cancers Based on Tcell Infiltration and PDL1. Cancer Res. 2015;75:2139–2145. DOI: 10.1158/00085472.CAN150255</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Teng M.W., Ngiow S.F., Ribas A. Classifying Cancers Based on Tcell Infiltration and PDL1. Cancer Res. 2015;75:2139–2145. DOI: 10.1158/00085472.CAN150255</mixed-citation><mixed-citation xml:lang="en">Beatty G.L., Gladney W.L. Immune escape mechanisms as a guide for cancer im munotherapy. Clin Cancer Res. 2015;21:687–692. DOI: 10.1158/10780432.CCR141860</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Beatty G.L., Gladney W.L. Immune escape mechanisms as a guide for cancer im munotherapy. Clin Cancer Res. 2015;21:687–692. DOI: 10.1158/10780432.CCR141860</mixed-citation><mixed-citation xml:lang="en">Boyd S.R., Tan D., Bunce C., Gittos A.., Neale M.H., Hungerford J.L, CharnockJones S., Cree I.A. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophthalmol. 2002;86(4):448–452. DOI: 10.1136/bjo.86.4.448</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Boyd S.R., Tan D., Bunce C., Gittos A.., Neale M.H., Hungerford J.L, CharnockJones S., Cree I.A. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophthalmol. 2002;86(4):448–452. DOI: 10.1136/bjo.86.4.448</mixed-citation><mixed-citation xml:lang="en">Чехун В. Воспаление и рак. Онкология. 2009;11(4):244–245. [Chekhun V. In flammation and cancer. Oncology = Onkologiya. 2009;11(4):244–245 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Чехун В. Воспаление и рак. Онкология. 2009;11(4):244–245.</mixed-citation><mixed-citation xml:lang="en">Savel’eva O.E., Perel’muter V.M., Tashireva L.A., Denisov E.V., Isaeva A.V. Recovery as a therapeutic target in the complex treatment of malignant tumors. Siberian jour nal of oncology = Sibirskiy onkologicheskiy zhurnal. 2017;16(3):65–78 (In Russ.). DOI: 10.21294/1814486120171636578</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Савельева О.Е., Перельмутер В.М., Таширева Л.А., Денисов Е.В., Исаева А.В. Воспаление как терапевтическая мишень при комплексном лечении злока чественных опухолей. Сибирский онкологический журнал. 2017;16(3):65–78. DOI: 10.21294/1814486120171636578</mixed-citation><mixed-citation xml:lang="en">Stitt A.W., Simpson D.A., Boocock C. Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intraocular tumours. J Pathol. 1998;186:306–312. DOI: 10.1002/(SICI)10969896(1998110)186:3&lt; 306::AIDPATH183&gt;3.0.CO;2B</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Stitt A.W., Simpson D.A., Boocock C. Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intraocular tumours. J Pathol. 1998;186:306–312. DOI: 10.1002/(SICI)10969896(1998110)186:3&lt; 306::AIDPATH183&gt;3.0.CO;2B</mixed-citation><mixed-citation xml:lang="en">Sheidlow T.G., Hooper P.L., Cruckley C. Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis. Invest Ophthalmol Vis Sci. 1999;40:S577.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Sheidlow T.G., Hooper P.L., Cruckley C. Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis. Invest Ophthalmol Vis Sci. 1999;40:S577.</mixed-citation><mixed-citation xml:lang="en">Cree I.A., Boyd S.R., Tan D. Angiogenesis in ocular melanoma: the role of VEGF and bFGF. Invest Ophthalmol Vis Sci. 1999;40:S577.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Cree I.A., Boyd S.R., Tan D. Angiogenesis in ocular melanoma: the role of VEGF and bFGF. Invest Ophthalmol Vis Sci. 1999;40:S577.</mixed-citation><mixed-citation xml:lang="en">Likhvantseva V.G., Anurova O.A., Astahova S.E., Vereshchagina M.V., Ovanesyan V.E., Stepanova E.V. Vascular endothelial growth factor expression in uveal melanoma. Оphthalmology in Russia = Oftal’mologiya. 2021;18(4):914–921 (In Russ) DOI: 10.18008/1816509520214914921</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Лихванцева В.Г., Анурова О.А., Астахова С.Е., Верещагина М.В., Ованесян В.Э., Степанова Е.В. Экспрессия фактора роста сосудистого эндотелия в увеальной меланоме. Офтальмология. 2021;18(4):914–921. DOI: 10.18008/1816509520214914921</mixed-citation><mixed-citation xml:lang="en">Лихванцева В.Г., Анурова О.А., Астахова С.Е., Верещагина М.В., Ованесян В.Э., Степанова Е.В. Экспрессия фактора роста сосудистого эндотелия в увеальной меланоме. Офтальмология. 2021;18(4):914–921. DOI: 10.18008/1816509520214914921</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
